Abstract

The Spike protein of SARS-CoV-2, its receptor binding domain (RBD), and its primary receptor ACE2 are extensively glycosylated. The impact of this post-translational modification on viral entry is yet unestablished. We expressed different glycoforms of the Spike-protein and ACE2 in CRISPR-Cas9 glycoengineered cells, and developed corresponding SARS-CoV-2 pseudovirus. We observed that N- and O-glycans had only minor contribution to Spike-ACE2 binding. However, these carbohydrates played a major role in regulating viral entry. Blocking N-glycan biosynthesis at the oligomannose stage using both genetic approaches and the small molecule kifunensine dramatically reduced viral entry into ACE2 expressing HEK293T cells. Blocking O-glycan elaboration also partially blocked viral entry. Mechanistic studies suggest multiple roles for glycans during viral entry. Among them, inhibition of N-glycan biosynthesis enhanced Spike-protein proteolysis. This could reduce RBD presentation on virus, lowering binding to host ACE2 and decreasing viral entry. Overall, chemical inhibitors of glycosylation may be evaluated for COVID-19.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. All plasmids generated by the authors will be deposited at Addgene.

Article and author information

Author details

  1. Qi Yang

    Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    Qi Yang, Co-author of a provisional patent application.(63/079,667).
  2. Thomas A Hughes

    Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    Thomas A Hughes, Co-author of a provisional patent application.(63/079,667).
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7887-6876
  3. Anju Kelkar

    Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    Anju Kelkar, Co-author of a provisional patent application.(63/079,667).
  4. Xinheng Yu

    Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    No competing interests declared.
  5. Kai Cheng

    Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    No competing interests declared.
  6. Sheldon Park

    Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    No competing interests declared.
  7. Wei-Chiao Huang

    Department of Biomedical Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    No competing interests declared.
  8. Jonathan F Lovell

    Department of Biomedical Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9052-884X
  9. Sriram Neelamegham

    Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, United States
    For correspondence
    neel@buffalo.edu
    Competing interests
    Sriram Neelamegham, Co-author of a provisional patent application.(63/079,667).
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1371-8500

Funding

National Institutes of Health (HL103411)

  • Sriram Neelamegham

National Institutes of Health (GM133195)

  • Sriram Neelamegham

National Institutes of Health (GM126537)

  • Sriram Neelamegham

National Institutes of Health (GM139160)

  • Sheldon Park
  • Sriram Neelamegham

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Malcolm J McConville, The University of Melbourne, Australia

Version history

  1. Received: July 29, 2020
  2. Accepted: October 24, 2020
  3. Accepted Manuscript published: October 26, 2020 (version 1)
  4. Version of Record published: November 24, 2020 (version 2)

Copyright

© 2020, Yang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 8,897
    views
  • 1,332
    downloads
  • 168
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Qi Yang
  2. Thomas A Hughes
  3. Anju Kelkar
  4. Xinheng Yu
  5. Kai Cheng
  6. Sheldon Park
  7. Wei-Chiao Huang
  8. Jonathan F Lovell
  9. Sriram Neelamegham
(2020)
Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration
eLife 9:e61552.
https://doi.org/10.7554/eLife.61552

Share this article

https://doi.org/10.7554/eLife.61552

Further reading

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Carlo Giannangelo, Matthew P Challis ... Darren J Creek
    Research Article

    New antimalarial drug candidates that act via novel mechanisms are urgently needed to combat malaria drug resistance. Here, we describe the multi-omic chemical validation of Plasmodium M1 alanyl metalloaminopeptidase as an attractive drug target using the selective inhibitor, MIPS2673. MIPS2673 demonstrated potent inhibition of recombinant Plasmodium falciparum (PfA-M1) and Plasmodium vivax (PvA-M1) M1 metalloaminopeptidases, with selectivity over other Plasmodium and human aminopeptidases, and displayed excellent in vitro antimalarial activity with no significant host cytotoxicity. Orthogonal label-free chemoproteomic methods based on thermal stability and limited proteolysis of whole parasite lysates revealed that MIPS2673 solely targets PfA-M1 in parasites, with limited proteolysis also enabling estimation of the binding site on PfA-M1 to within ~5 Å of that determined by X-ray crystallography. Finally, functional investigation by untargeted metabolomics demonstrated that MIPS2673 inhibits the key role of PfA-M1 in haemoglobin digestion. Combined, our unbiased multi-omic target deconvolution methods confirmed the on-target activity of MIPS2673, and validated selective inhibition of M1 alanyl metalloaminopeptidase as a promising antimalarial strategy.

    1. Biochemistry and Chemical Biology
    Ornella Bimai, Ipsita Banerjee ... Derek T Logan
    Research Article

    A small, nucleotide-binding domain, the ATP-cone, is found at the N-terminus of most ribonucleotide reductase (RNR) catalytic subunits. By binding adenosine triphosphate (ATP) or deoxyadenosine triphosphate (dATP) it regulates the enzyme activity of all classes of RNR. Functional and structural work on aerobic RNRs has revealed a plethora of ways in which dATP inhibits activity by inducing oligomerisation and preventing a productive radical transfer from one subunit to the active site in the other. Anaerobic RNRs, on the other hand, store a stable glycyl radical next to the active site and the basis for their dATP-dependent inhibition is completely unknown. We present biochemical, biophysical, and structural information on the effects of ATP and dATP binding to the anaerobic RNR from Prevotella copri. The enzyme exists in a dimer–tetramer equilibrium biased towards dimers when two ATP molecules are bound to the ATP-cone and tetramers when two dATP molecules are bound. In the presence of ATP, P. copri NrdD is active and has a fully ordered glycyl radical domain (GRD) in one monomer of the dimer. Binding of dATP to the ATP-cone results in loss of activity and increased dynamics of the GRD, such that it cannot be detected in the cryo-EM structures. The glycyl radical is formed even in the dATP-bound form, but the substrate does not bind. The structures implicate a complex network of interactions in activity regulation that involve the GRD more than 30 Å away from the dATP molecules, the allosteric substrate specificity site and a conserved but previously unseen flap over the active site. Taken together, the results suggest that dATP inhibition in anaerobic RNRs acts by increasing the flexibility of the flap and GRD, thereby preventing both substrate binding and radical mobilisation.